🇺🇸 FDA
Pipeline program

131I-apamistamab

AIM-300

Phase 3 small_molecule active

Quick answer

131I-apamistamab for Acute Leukemia is a Phase 3 program (small_molecule) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Actinium Pharmaceuticals
Indication
Acute Leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials